Introduction:
The global biosimilar market continues to expand rapidly, driven by the increasing demand for affordable biologic drugs and the growing focus on healthcare cost containment. According to industry reports, the global biosimilar market is expected to reach $35 billion by 2026, with a CAGR of 30%. As the market evolves, collaboration models between companies are becoming increasingly important for driving innovation and market growth.
Spotlight Top 50 Emerging Biosimilar Collaboration Models Worldwide 2026:
1. Pfizer- Biocon: This collaboration has resulted in the successful development and commercialization of biosimilar products in key markets, contributing to a significant market share in the biosimilar segment.
2. Amgen- Allergan: A strategic partnership between these two companies has led to the launch of several biosimilar products, strengthening their position in the global biosimilar market.
3. Celltrion- Teva: This collaboration has enabled the companies to leverage their expertise in biosimilar development and commercialization, resulting in a strong portfolio of biosimilar products.
4. Samsung Bioepis- Merck: The partnership between these two companies has been instrumental in expanding the availability of biosimilar drugs in various markets, driving market growth.
5. Sandoz- Coherus Biosciences: This collaboration has enabled the companies to bring high-quality biosimilar products to market, meeting the increasing demand for affordable biologic drugs.
6. Boehringer Ingelheim- Fresenius Kabi: The collaboration between these companies has resulted in the successful development and commercialization of biosimilar products, expanding their presence in the biosimilar market.
7. Mylan- BioXpress Therapeutics: This strategic partnership has enabled the companies to accelerate the development of biosimilar products, addressing the unmet medical needs of patients worldwide.
8. Biogen- Fujifilm Kyowa Kirin Biologics: The collaboration between these companies has led to the successful launch of biosimilar products, contributing to market growth and innovation.
9. Dr. Reddy’s Laboratories- Intas Pharmaceuticals: This partnership has allowed the companies to strengthen their biosimilar portfolios and expand their presence in key markets.
10. AbbVie- Amgen: The collaboration between these companies has resulted in the successful development and commercialization of biosimilar products, enhancing their market competitiveness.
Insights:
The biosimilar market is poised for significant growth in the coming years, driven by the increasing demand for affordable biologic drugs and the expanding biosimilar pipeline. Collaborations between companies will play a crucial role in driving innovation and market expansion. According to industry reports, the biosimilar market is expected to witness a CAGR of 30% from 2021 to 2026, reaching a market size of $35 billion by 2026. As companies continue to invest in biosimilar development and commercialization, strategic partnerships will be key to unlocking new opportunities and driving market success.
Related Analysis: View Previous Industry Report
